Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558271 | PMC |
http://dx.doi.org/10.1016/j.jdcr.2019.03.024 | DOI Listing |
Int J Dermatol
January 2025
Department of Dermatology, Fukushima Medical University, Fukushima, Japan.
Eur J Case Rep Intern Med
December 2019
Rheumatology Department, University Hospital of Heraklion, Crete, Greece.
Objectives: Baricitinib is an orally active Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis (RA).
Materials And Methods: Here, we report the case of a 56-year-old Caucasian male diagnosed with RA who developed palmoplantar pustulosis (PPP) while being treated with baricitinib.
Results: The patient's PPP resolved after discontinuation of baricitinib and recurred when this was restarted.
JAAD Case Rep
June 2019
Department of Dermatology, Aichi Medical University School of Medicine, Nagakute, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!